VEAPS: Vitamin E Atherosclerosis Prevention Study

Completed · Phase 2/Phase 3

Conditions studied: Atherosclerosis

In brief

The purpose of this study is to examine whether vitamin E (DL-alpha-tocopherol) supplementation will reduce the progression of early atherosclerosis in healthy individuals over 40 years of age with low-density lipoprotein (LDL) cholesterol levels greater than or equal to 130mg/dL.

Key facts

Study ID

NCT00114387

Run by

National Institute on Aging (NIA)

People needed

353

Starts

1996-07-01

Expected to finish

2000-09-01

Last updated by the study team

2009-12-11

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male or female
• 40 years or older
• Fasting LDL-C level 130 mg/dL or greater, TG (triglyceride) levels 500mg/dL or lower

You may not qualify if…

• Any clinical signs or symptoms of cardiovascular disease (CVD)
• Diabetes mellitus or fasting serum glucose 140mg/dL or greater
• Regular vitamin E supplementation for more than 1 year
• Lipid standardized plasma vitamin E levels greater than 35 micromoles per liter (μmol/L)
• Uncontrolled hypertension (diastolic blood pressure 100 mmHg or greater)
• Thyroid disease (untreated)
• Renal insufficiency (serum creatinine greater than 2.5 mg/dL)
• Life threatening disease with prognosis less than 5 years
• Alcohol intake greater than 5 drinks per day (1 drink = 1 1/2 oz distilled spirits, 4 oz wine, or 12 oz beer) or substance abuse (intravenous drug abuse, cocaine use)

Where it is running

• Atherosclerosis Research Unit, Division of Cardiovascular Medicine, Department of Medicine — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.